Actively personalized vaccination trial for newly diagnosed glioblastoma
Abstract
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors 1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neoepitopes are thought to be essential 3. There is limited intratumoural infiltration of immune cells 4 in glioblastoma and these tumours contain only 30-50 non-synonymous mutations 5. Exploitation of the full repertoire of tumour antigens-that is, both unmutated antigens and neoepitopes-may offer more effective immunotherapies, especially for tumours with a low mutational load. Here, in the phase I trial GAPVAC-101 of the Glioma Actively Personalized Vaccine Consortium (GAPVAC), we integrated highly individualized vaccinations with both types of tumour antigens into standard care to optimally exploit the limited target space for patients with newly diagnosed glioblastoma. Fifteen patients with glioblastomas positive for human leukocyte antigen (HLA)-A*02:01 or HLA-A*24:02 were treated with a vaccine (APVAC1) derived from a premanufactured library of unmutated antigens followed by treatment with APVAC2, which preferentially targeted neoepitopes. Personalization was based on mutations and analyses of the transcriptomes and immunopeptidomes of the individual tumours. The GAPVAC approach was feasible and vaccines that had poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable safety and strong immunogenicity. Unmutated APVAC1 antigens elicited sustained responses of central memory CD8+ T cells. APVAC2 induced predominantly CD4+ T cell responses of T helper 1 type against predicted neoepitopes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both the GAPVAC-101 and IMA950 immunotherapeutics were well tolerated and induced epitope-specific CD8+ T-cell responses.
“Both immunotherapeutics, which shared some peptides, were well tolerated and induced epitope-specific CD8+ T-cell responses [14, 15].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [14]
The epitopes encoded by CVGBM have previously induced T-cell responses in patients with GBM when given as peptide-based immunotherapeutics in the GAPVAC-101 or IMA950 studies.
“The epitopes encoded by CVGBM have previously induced T-cell responses in the GAPVAC-101 or IMA950 studies in patients with GBM when given as peptide-based immunotherapeutics in combination with adjuvants [14, 15].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [14]
CVGBM encodes eight epitopes that are frequently presented on the surface of GBM tumour samples.
“CVGBM encodes eight epitopes that are frequently presented on the surface of GBM tumour samples and have induced immune responses in previous clinical trials as peptide-based immunotherapeutics [14, 15].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [14]
The eight CVGBM-encoded epitopes have induced immune responses in previous clinical trials as peptide-based immunotherapeutics.
“CVGBM encodes eight epitopes that are frequently presented on the surface of GBM tumour samples and have induced immune responses in previous clinical trials as peptide-based immunotherapeutics [14, 15].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [14]
Cites
1 retracted
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma
Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., ROSNER, I. A., López‐Larrea, C., Hilf, N., Kuttruff, S., Song, C., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.000792 · Cited by 61 · see citing works
Self-citationRetractedFast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607 · see citing works
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849 · see citing works
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Self-citationMapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165 · see citing works
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works
Self-citationDifferentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · see citing works
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works
Enhancements and modifications of primer design program Primer3
Kõressaar, T., & Remm, M. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm091 · Cited by 2,618 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
Self-citationThe Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,875 · see citing works
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · see citing works
Self-citationPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · see citing works
Self-citationWeller, M., Butowski, N. A., Tran, D. D., Recht, L. D., Lim, M. K., Hirte, H. W., Ashby, L. S., Mechtler, L. L., Goldlust, S. A., IWAMOTO, F. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,138 · see citing works
Self-citationBouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857 · see citing works
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C. A., Staehler, M. D., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788 · see citing works
Self-citationHigh-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. E. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 773 · see citing works
Immunogenicity of somatic mutations in human gastrointestinal cancers
Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729 · see citing works
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Woroniecka, K. I., Chongsathidkiet, P., Rhodin, K. E., Kemeny, H. R., Dechant, C. A., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 651 · see citing works
Okada, H., Kaliński, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7744 · Cited by 570 · see citing works
Self-citationImmune epitope database analysis resource
Kim, Y., Ponomarenko, J. V., Zhu, Z., Tamang, D., Wang, P., Greenbaum, J., Lundegaard, C., Sette, A., Lund, O., Bourne, P. E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks438 · Cited by 511 · see citing works
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 495 · see citing works
Cohen, C. J., Li, Y. F., El‐Gamil, M., Robbins, P. F., Rosenberg, S. A., & Morgan, R. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3986 · Cited by 363 · see citing works
Generation of peptide–MHC class I complexes through UV-mediated ligand exchange
Rodenko, B., Toebes, M., Hadrup, S. R., van Esch, W. J. E., Molenaar, A. M., Schumacher, T. N., & Ovaa, H. (2006) · Nature Protocols · doi:10.1038/nprot.2006.121 · Cited by 320 · see citing works
Hadrup, S. R., Bakker, A. H., Shu, C. J., Andersen, R. S., van Veluw, J., Hombrink, P., Castermans, E., thor Straten, P., Blank, C., Haanen, J. B., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1345 · Cited by 306 · see citing works
Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C. I., Chang, E. F., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 290 · see citing works
Santegoets, S. J. A. M., Dijkgraaf, E. M., Battaglia, A., Beckhove, P., Britten, C. M., Gallimore, A., Godkin, A. J., Gouttefangeas, C., de Gruijl, T. D., Koenen, H. J. P. M., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1729-x · Cited by 213 · see citing works
Self-citationExploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., et al. (2012) · Brain · doi:10.1093/brain/aws042 · Cited by 201 · see citing works
Self-citationIntegrated functional genomics approach for the design of patient-individual antitumor vaccines.
Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F., Walter, S., Schoor, O., Kurek, R., Loeser, W., Bichler, K., Wernet, D., et al. (2002) · PubMed · Cited by 189 · see citing works
Self-citationBertoletti, A., Chisari, F. V., Penna, A., Guilhot, S., Galati, L., Missale, G., Fowler, P., Schlicht, H. J., Vitiello, A., & Chesnut, R. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.2376-2380.1993 · Cited by 173 · see citing works
Rampling, R., Peoples, S., Mulholland, P. J., James, A., Al‐Salihi, O., Twelves, C., McBain, C. A., Jefferies, S., Jackson, A., Stewart, W. B., Jr., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0506 · Cited by 173 · see citing works
Self-citationVaccine-based immunotherapeutic approaches to gliomas and beyond
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M., & Sampson, J. H. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.64 · Cited by 161 · see citing works
Self-citationUse of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens
Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., Schachter, J., Rosenberg, S. A., Besser, M. J., Admon, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6960 · Cited by 148 · see citing works
Self-citationBritten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S. D., Ottensmeier, C. H. H., Mander, A., Walter, S., Paschen, A., Müller‐Berghaus, J., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0378-0 · Cited by 143 · see citing works
Self-citationMorse, M. A., Chapman, R., Powderly, J. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0891 · Cited by 141 · see citing works
Lawson, D. H., Lee, S., Zhao, F., Tarhini, A. A., Margolin, K. A., Ernstoff, M. S., Atkins, M. B., Cohen, G. I., Whiteside, T. L., Butterfield, L. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0500 · Cited by 141 · see citing works
Livingston, B. D., Crimi, C., Grey, H. M., Ishioka, G. Y., Chisari, F. V., Fikes, J. D., Grey, H. M., Chesnut, R. W., & Sette, A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.3.1383 · Cited by 139 · see citing works
Singh‐Jasuja, H., Emmerich, N., & Rammensee, H. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0480-x · Cited by 124 · see citing works
Self-citationMapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry
Freudenmann, L. K., Marcu, A., & Stevanović, S. (2018) · Immunology · doi:10.1111/imm.12936 · Cited by 109 · see citing works
Self-citationHarmonization of Immune Biomarker Assays for Clinical Studies
van der Burg, S. H., Kalos, M. D., Gouttefangeas, C., Janetzki, S., Ottensmeier, C. H. H., Welters, M. J. P., Romero, P. J., Britten, C. M., & Hoos, A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002785 · Cited by 97 · see citing works
Self-citationLoeffler, M. W., Chandran, P. A., Laske, K., Schroeder, C., Bonzheim, I., Walzer, M., Hilke, F. J., Trautwein, N., Kowalewski, D. J., Schuster, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.027 · Cited by 92 · see citing works
Self-citationKobayashi, E., Mizukoshi, E., Kishi, H., et al. (2013) · Nature Medicine · doi:10.1038/nm.3358 · Cited by 87 · see citing works
Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26365 · Cited by 70 · see citing works
Self-citationStraten, P. T., Guldberg, P., Grønbæk, K., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.443 · Cited by 66 · see citing works
Walter, S., Herrgen, L., Schoor, O., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.4974 · Cited by 64 · see citing works
Self-citationHarmonization of the intracellular cytokine staining assay
Welters, M. J. P., Gouttefangeas, C., Ramwadhdoebé, T. H., Letsch, A., Ottensmeier, C. H. H., Britten, C. M., & van der Burg, S. H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1282-9 · Cited by 50 · see citing works
Self-citationConcepts in glioma immunotherapy
Platten, M., Bunse, L., Wick, W., & Bunse, T. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1874-x · Cited by 50 · see citing works
Self-citationTumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells
Hadrup, S. R., Brændstrup, O., Jacobsen, G. K., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21894 · Cited by 44 · see citing works
Stanke, J., Hoffmann, C., Erben, U., et al. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.06.005 · Cited by 22 · see citing works
Straten, P. T., Dahl, C., Schrama, D., Pedersen, L. Ø., Andersen, M. H., Seremet, T., Bröcker, E., Guldberg, P., & Becker, J. C. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0023-8 · Cited by 20 · see citing works
Grimm, E. A., Bruner, J. M., Carinhas, J., et al. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741334 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581 · see citing works
Self-citationWen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168 · see citing works
Self-citationOtt, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738 · see citing works
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597 · see citing works
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524 · see citing works
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500 · see citing works
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · see citing works
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356 · see citing works
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342 · see citing works
Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250 · see citing works
Self-citationEngineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208 · see citing works
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163 · see citing works
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76 · see citing works
van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63 · see citing works
Self-citationRole of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)
Naser, R., Fakhoury, I., El‑Fouani, A., Abi‑Habib, R., & El‑Sibai, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5471 · Cited by 61 · see citing works
Immunotherapy in Glioblastoma: A Clinical Perspective
Desbaillets, N., & Hottinger, A. F. (2021) · Cancers · doi:10.3390/cancers13153721 · Cited by 31 · see citing works
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Kilian, M., Friedrich, M., Sanghvi, K., Green, E., Pusch, S., Kawauchi, D., Löwer, M., Sonner, J. K., Krämer, C., Zaman, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1881 · Cited by 18 · see citing works
Self-citationImmunotherapeutic advances in glioma management: The rise of vaccine‐based approaches
Andrew Awuah, W., Shah, M. H., Tan, J. K., Ranganathan, S., Sanker, V., Darko, K., Tenkorang, P. O., Adageba, B. B., Ahluwalia, A., Shet, V., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70013 · Cited by 14 · see citing works
Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma
Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-025-04178-x · Cited by 9 · see citing works
“Two examples are the Phase I GAPVAC-101 study [14] and the Phase I/II IMA950 study [15], which tested peptide-based immunotherapeutics containing epitopes from unmutated TAAs that are either over-expressed or over-presented in GBM.”
Influential
- Authors
- Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A., Skardelly, M., Migliorini, D., Kroep, J. R., Idorn, M., Rodon, J., Piró, J., Poulsen, H. S., Shraibman, B., McCann, K., Mendrzyk, R., Löwer, M., Stieglbauer, M., Britten, C. M., Capper, D., Welters, M. J. P., Sahuquillo, J., Kiesel, K., Derhovanessian, E., Rusch, E., Bunse, L., Song, C., Heesch, S., Wagner, C., Kemmer-Brück, A., Ludwig, J., Castle, J. C., Schoor, O., Tadmor, A. D., Green, E., Fritsche, J., Meyer, M., Pawlowski, N., Dorner, S., Hoffgaard, F., Rössler, B., Maurer, D., Weinschenk, T., Reinhardt, C., Huber, C., Rammensee, H.-G., Singh-Jasuja, H., Sahin, U., Dietrich, P.-Y., & Wick, W.
- Affiliations
- Immatics Biotechnologies (Germany) (DE)
- BioNTech (Germany) (DE)
- German Cancer Research Center (DE)
- University of California, San Francisco (US)
- Rigshospitalet (DK)
- Technion – Israel Institute of Technology (IL)
- University of Southampton (GB)
- Universitätsklinikum Tübingen (DE)
- University Hospital of Geneva (CH)
- Leiden University Medical Center (NL)
- University of Copenhagen (DK)
- The University of Texas MD Anderson Cancer Center (US)
- University of Tübingen (DE)
- GlaxoSmithKline (United Kingdom) (GB)
- Vall d'Hebron Hospital Universitari (ES)
- Agenus (United States) (US)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Wick, Wolfgang
- ORCID
- Hilf, Norbert
- Kuttruff-Coqui, Sabrina
- Stevanović, Stefan
- Gouttefangeas, Cécile
- Platten, Michael
- Tabatabai, Ghazaleh
- Ponsati, Berta
- Okada, Hideho
- Lassen, Ulrik
- Admon, Arie
- Ottensmeier, Christian H.
- Kreiter, Sebastian
- Skardelly, Marco
- Migliorini, Denis
- Kroep, Judith R.
- Idorn, Manja
- Rodon, Jordi
- Poulsen, Hans S.
- McCann, Katy
- Mendrzyk, Regina
- Britten, Cedrik M.
- Capper, David
- Welters, Marij J. P.
- Sahuquillo, Juan
- Bunse, Lukas
- Wagner, Claudia
- Castle, John C.
- Schoor, Oliver
- Tadmor, Arbel D.
- Green, Edward
- Fritsche, Jens
- Hoffgaard, Franziska
- Maurer, Dominik
- Weinschenk, Toni
- Reinhardt, Carsten
- Rammensee, Hans-Georg
- Wick, Wolfgang
- Venue
- Nature
- Published
- 2018-12-19
- Volume
- 565
- Issue
- 7738
- Pages
- 240-245
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2904210127
- Cited by
- 938
- References
- 58
- Citations by year
- 2026: 76 · 2025: 108 · 2024: 102 · 2023: 120 · 2022: 142 · 2021: 157 · 2020: 153 · 2019: 77 · 2018: 2 · 2015: 1
- FWCI
- 55.70
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-02-07)
- Open access
- closed
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Funders
- Cancer Research UK (15951)
- Medical Research Council (MR/P024351/1)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- glioblastoma, personalized cancer vaccines, neoantigens, peptide vaccine, immunopeptidome, tumor transcriptome, HLA-A*0201, HLA-A*24:02, GM-CSF adjuvant, CD8+ T cell responses, CD4+ T cell responses, immunotherapy
- MeSH terms
- Adult, Aged, Antigens, Neoplasm, Female, Glioblastoma, T-Lymphocytes, Helper-Inducer, Humans, Immunologic Memory, Male, Middle Aged, HLA-A Antigens, Treatment Outcome, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Cancer Vaccines, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
